PegIFN beta-1a for relapsing-remitting MS: 2 years are better than 1

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • 2 y of peginterferon (pegIFN) beta-1a was superior to 1 y in patients with relapsing-remitting multiple sclerosis (MS).

Why this matters

  • Long-term efficacy of peginterferon beta-1a is unknown.

Key results

  • Compared with the delayed treatment group, the peginterferon bet...